" do you think
by: slgonzalez
6212 of 6213
Do you think that xoma's pre-specified mortality target, their final total of patients enrolled, (yes, and our consideration
of the 62 that expired before they could get in the trial as an indicator of what meningo can do) has the
ingredients for an outright statistical winner? A very clear YES to the FDA, a strong message to the
scientific community for niche indication, head turner, PIs of multiple specialties trying to work with BPI
and related proteins, visiting Xoma with study proposals. This is fantasy, but what if? "
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
I have answered that for myself. YES, I have. Would seem institutional interest in XOMA continues. The only place the institutions can get shares is from retail. Low volume might indicate lack of eagerness to sell at these prices and of course lack of desire by institutions to just buy at any price. Think retail will let go of stock if and as it moves up. The institutions should have little trouble filling their needs without bumping the stock up too much. Why? Retail holders are tired out. Fear of general market. The, "now I can get out even", syndrome. "It is going to fall back and I can buy it cheaper." "Grass is greener, cheaper on the other side of the street."
Being able to track "institutional" interest and percent of volume is quite important now. According to Sluggers original post on this, he was not seeing this type of thing before. |
